Review anchor
Histone deacetylase 6
SINGLE PROTEIN · Mus musculus
As of 2026-09-14
Evidence Snapshot
Histone deacetylase 6
CHEMBL2878
SINGLE PROTEIN
Mus musculus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Histone deacetylase 6 as ChEMBL target CHEMBL2878, mapped to UniProt Q9Z2V5. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2878
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9Z2V5
Protein deacetylase HDAC6
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Histone deacetylase 6 matters
Histone deacetylase 6 is reviewed as Protein deacetylase HDAC6 (UniProt Q9Z2V5); the current evidence base includes 1 approved drug, 157 compounds, and 89 assays, with lead potency reaching pChEMBL 9.2.
Protein context
Protein deacetylase HDAC6
Protein deacetylase HDAC6 Sequence length is 1149 aa.
Review this target as Histone deacetylase 6, mapped to UniProt Q9Z2V5. ChEMBL maps the protein component as Protein deacetylase HDAC6. Sequence length is 1149 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9Z2V5
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 157 compounds, and 89 assays for this target. The dominant activity type is IC50. CHEMBL343448 is the current potency anchor at pChEMBL 9.2.
Use CHEMBL343448 as the tractability anchor when discussing potency (pChEMBL 9.2).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 9.2
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Histone deacetylase 6 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9Z2V5, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
157
Total Compounds
89
Total Assays
1
Approved Drugs
IC50: 106.0, EC50: 3.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL343448
|
9.2 | IC50 | Approved |
|
|
No preferred name
CHEMBL99
|
8.6 | IC50 | — |
|
|
No preferred name
CHEMBL2018302
|
8.4 | IC50 | — |
|
|
No preferred name
CHEMBL394261
|
8.1 | IC50 | — |
|
|
No preferred name
CHEMBL4636622
|
8.0 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ROMIDEPSIN
CHEMBL343448
|
2009 |
Source Header